Peramivir Trihydrate

Modify Date: 2024-01-01 23:33:39

Peramivir Trihydrate structure	Common Name	Peramivir Trihydrate
	CAS Number	1041434-82-5	Molecular Weight	382.453
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₅H₃₄N₄O₇	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Peramivir Trihydrate

Peramivir (RWJ 270201; Rapiacta; BCX 1812) is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.IC50 Value: 0.09 nMTarget: NeuraminidasePeramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. From Wikipedia

Name	peramivir
Synonym	More Synonyms

Description	Peramivir (RWJ 270201; Rapiacta; BCX 1812) is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.IC50 Value: 0.09 nMTarget: NeuraminidasePeramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. From Wikipedia
Related Catalog	Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Infection
References	[1]. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM.Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09.PLoS One. 2012;7(6):e40261. [2]. Sakata H.Clinical efficiency in children treated with intravenous drip infusion of peramivirJpn J Antibiot. 2011 Dec;64(6):383-7. [3]. Abed Y, Pizzorno A, Boivin G.Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80. [4]. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother. 2012 May 29. [5]. Yu Y, Garg S, Yu PA, Kim HJ, Patel A, Merlin T, Redd S, Uyeki TM.Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.Clin Infect Dis. 2012 Jul;55(1):8-15.

Description

Related Catalog

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

References

[1]. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM.Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09.PLoS One. 2012;7(6):e40261.

[2]. Sakata H.Clinical efficiency in children treated with intravenous drip infusion of peramivirJpn J Antibiot. 2011 Dec;64(6):383-7.

[3]. Abed Y, Pizzorno A, Boivin G.Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80.

[4]. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother. 2012 May 29.

[5]. Yu Y, Garg S, Yu PA, Kim HJ, Patel A, Merlin T, Redd S, Uyeki TM.Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.Clin Infect Dis. 2012 Jul;55(1):8-15.